- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05000099
the Role of Technology in Elderly Patients (SILVER)
Fighting Against Social Isolation in Times of Pandemic Corona Virus-19: the Role of Technology in Elderly Patients: The SILVER Study
Starting from December 2019, the Severe Acute Respiratory Syndrome Corona Virus-2 (SARS-COV-2) disease spread rapidly from China into the world, with about two Mio cases confirmed around the world. In Switzerland, more than 26'000 cases have been confirmed so far, and health authorities declared in March the needs for social isolation and have banned visits to hospitalized patients and to nursing home residents. Loneliness and isolation is a significant concern for the elderly patients as well as for their families that may significantly affect physical and mental health in both.
SILVER aims to evaluate the role of programmed video calls with families:
- on mood, anxiety, fear of death and pain perception in patients hospitalized or in nursing homes during the SARS-COV-2 pandemic.
- in relieving the familiar caregiver anxiety and fear of death of others
- in relieving the professional caregiver anxiety.
SILVER is an international study involving both acute, rehabilitation geriatric units and nursing homes; we will enroll all the patients present in the participating centers. Patients will be allowed to chose between video and phone calls, the following dimensions will be evaluated:
- Delirium risk: using the Confusion Assessment Method (CAM)
- Mood: using the 5-item Geriatric Depression Scale (GDS)
- Anxiety: using the Clinical Anxiety Scale (GAS).
- Fear of death (self and others): using the Collett-Lester scale. In parallel, health professionals and family caregivers will be evaluated for anxiety at baseline and every week after intervention set-up by the Clinical Anxiety Scale (CAS). Family caregivers will also be evaluated with the fear of death scale (sub-scale fear of death of others).
Finally, to evaluate the appreciation for video call communication in patients and caregivers we will use a Likert scale.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Aims.
- To evaluate the role of video calls with families on mood, anxiety, fear of death and pain perception in patients hospitalized or in nursing homes during the SARS-CoV-2 pandemic.
- To evaluate the role of video calls in relieving family caregivers' anxiety and fear of death of their loved one.
- To evaluate the role of video calls in relieving health professionals' anxiety.
Methods. In order to reduce social isolation from their relatives and friends patients will be helped in joining them through video-calls thanks to the use of dedicated tablets and to the assistance provided by nurses, assistant-nurses, occupational therapists or neuropsychologists.
Population selection. All the patients in the participating centers fulfilling inclusion/exclusion criteria will be enrolled in SILVER.
Patients will be asked to chose between video and phone call, phone call will be allowed without any restriction to both video and usual care groups.
standardization of video calls: Two video-calls of maximum 15' will be administered every week; in addition, patients will be allowed to do video-call upon request. Video-calls will be performed using Skype or WhatsApp video or Face-time, the use of others app will be evaluated upon family's request.
Data collection for primary and secondary outcomes. Patients will be evaluated at baseline and every week with standardized scales to assess their mood, anxiety and delirium symptoms.
At baseline and at the end of the intervention we will evaluate the overall appreciation of the video call by the patients, their family caregiver, and the health professionals using a Likert scale and Anxiety: using the Geriatric Anxiety Scale (GAS).
In order to clarify the role of social connection through video calls on the patients' health, we will evaluate at baseline and after one week :
- Mood: using the 5-items Geriatric Depression Scale (GDS-5)
- Fear of death (self and others): using the Collett-Lester scale
- Delirium risk: using the Confusion Assessment Method (CAM) will be evaluated every day and will be analyzed ad day of delirium weekly.
In addition, the effect of video calls in professionals and in family caregivers will be evaluated as follows:
family and professional caregivers will be evaluated for anxiety at baseline and the end of intervention set-up by the Clinical anxiety (CAS). Familiar care-givers will also be evaluated with the fear of death scale (sub-scale fear of death of others) at the baseline and after one week.
Collection of other data.
In order to correct the statistical analyses for possible confounding variables the following data will be collected:
Age, gender, years of school, duration of hospitalization , type of hospital discharge, Mini Mental State Examination (MMSE), Clinical Dementia Rating (CDR) scale, Cumulative Illness Rating Scale (CIRS) index, Activity of Daily Living (ADL), Instrumental Activities of Daily Living (IADL).
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Lausanne, Switzerland, 1012
- Patrizia D'amelio
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- patients of 65 years and older hospitalized in the participating unit during the absence of visits due to the SARS-CoV2 pandemic.
- Patients and families willing to participate.
Exclusion Criteria:
- patients or families who refuse to participate.
- Clinical Dementia Rating (CDR) equal or higher than two.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
phone calls
patients choosing phone calls as preferred communication technique
|
A tablet for video-calls will be available for patients and families.
Two video-calls of maximum 15' will be organized every week; in addition, patients will be allowed to do video-call upon request.
Video-calls will be performed using Skype or WhatsApp video or Face-time
Other Names:
|
|
video call
patients choosing video calls as preferred communication technique
|
A tablet for video-calls will be available for patients and families.
Two video-calls of maximum 15' will be organized every week; in addition, patients will be allowed to do video-call upon request.
Video-calls will be performed using Skype or WhatsApp video or Face-time
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
4-point likert scale (LKRT)
Time Frame: 0-7 days
|
appreciation of video calls by patients and families rage 0-4, 4 represent the better outcome
|
0-7 days
|
|
Geriatric anxiety scale (GAS-10)
Time Frame: 0-7 days
|
measure of anxiety, The GAS-10 form, contains a total of 10 items, the answers are yes or no and the possible scores range from 0 to 10, with a cut-off point for anxiety at 6.
The higher the score, the greater the anxiety.
|
0-7 days
|
|
Collett Lester Fear of Death scale (CL-FOD) for self and others
Time Frame: 0-7 days
|
fear of death scale of patients, The CL-FODS contains 28 items, with seven items on each of the four subscales: Fear of Death of Self, Dying of Self, Death of Others, and Dying of Others.
It is answered on a 5-point Likert format anchored as follows: 1 (not) and 5 (very).
The total score in each subscale could range from 7 to 35, with higher scores denoting higher anxiety from death or dying.
|
0-7 days
|
|
geriatric depression scale (GDS-5)
Time Frame: 0-7 days
|
mood evaluation for patients.
the GDS-5 contains 5 items, the total score range from 0 to 5, the clinical cut-off for suspicion of depression is 2
|
0-7 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Collett Lester Fear of Death scale (CL-FOD) for others
Time Frame: 0-7 days
|
fear of death scale of others for family
|
0-7 days
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2020-01125
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
Massachusetts General HospitalRecruitingDepression | Depression - Major Depressive Disorder | Depression Chronic | Depression in Adults | Depression Disorders | Depression DisorderUnited States
-
University of California, San FranciscoNational Center for Complementary and Integrative Health (NCCIH)Active, not recruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
ProgenaBiomeWithdrawnDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Sorlandet Hospital HFUniversity of Oslo; Karolinska Institutet; Australian Catholic University; Helse...RecruitingAnxiety | Anxiety Depression | Depression Anxiety Disorder | Depression - Major Depressive DisorderNorway
-
Lipocine Inc.CompletedDepression, Postpartum | Postnatal Depression | Peripartum Depression | Depression, Post-Partum | Postpartum Depression (PPD) | Post-Natal DepressionUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Vituity PsychiatryActive, not recruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Kolby Walker, DO; Brittany KimbleRecruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
University of CincinnatiNational Center for Complementary and Integrative Health (NCCIH)RecruitingMild DepressionUnited States
-
University of MinnesotaCompletedDepression SymptomsUnited States
Clinical Trials on video calls
-
Umeå UniversityForte; Västerbotten County Council, SwedenNot yet recruitingOverweight and Obesity
-
US Department of Veterans AffairsCompletedSpinal Cord InjuryUnited States
-
University of Wisconsin, MadisonCompleted
-
University of PennsylvaniaCompleted
-
Virginia Polytechnic Institute and State UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Carilion... and other collaboratorsCompletedDiabetes PreventionUnited States
-
Medical University of South CarolinaCompletedSystemic Lupus ErythematosusUnited States
-
Brigham and Women's HospitalCompletedIn Vitro Fertilization | Psychological StressUnited States
-
Indiana UniversityUniversity of Washington; Consumer Wellness Solutions; Kaiser Foundation Hospitals...CompletedSmoking CessationUnited States
-
University of Alabama at BirminghamCompletedDisability Physical | Chronic Conditions, Multiple | Chronic ConditionUnited States
-
Ohio State UniversityCompleted